ArticleClinical drug investigation2023

Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?

Wenhua Wu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.